TherapeuticsMD Elects Jules A. Musing to Board of Directors
BOCA RATON, Fla. -- May 16, 2013
TherapeuticsMD, Inc. (NYSE MKT: TXMD), a women’s healthcare company focused on
developing and commercializing products targeted exclusively for women, today
announced the election of Jules A. Musing, a former senior executive at
Johnson & Johnson, to its Board of Directors, effective immediately.
Mr. Musing has more than 36-years’ experience in the pharmaceutical and
biotechnology industry and has been President and Managing Director of Johnson
& Johnson subsidiary companies in the United States and Europe; President of
Ares Serono, Inc. in the United States; and Executive Vice President of Ares
Serono in North and Latin America.
In the course of his career at Johnson & Johnson, Mr. Musing was responsible
for worldwide licensing and acquisition of pharmaceutical and biotechnology
products and technologies, as well as the establishment of strategic
alliances. This included the establishment of new scientific, technology and
product collaborations in various therapeutic areas; the negotiation of
licensing and alliance agreements with biotechnology and pharmaceutical
companies worldwide; and the partnering, spin-out and out-licensing of company
pharmaceutical and biotechnology assets. In this position he negotiated and
signed several multi-million dollar deals with small, medium and large
pharmaceutical and biotechnology companies on a global basis.
He also has been on the Board of Directors of Johnson & Johnson companies in
Germany, France, Italy and the UK and has been a member of the Management
Board of Ortho Biotech (a Johnson & Johnson biotechnology company) in the
United States and Europe.
Early on in his career, Mr. Musing was responsible for the business
development activities of Janssen Pharmaceutica in S.E. Asia, where he was
instrumental in the establishment of Johnson & Johnson pharmaceutical
subsidiaries in Japan, Australia, South Africa, Thailand, and other S.E. Asian
countries. He also was Vice President, Marketing International for the Janssen
Group of Companies Worldwide.
“We are pleased to welcome Mr. Musing to the Board,” said the Honorable Tommy
G. Thompson, Chairman of the Board, TherapeuticsMD. “During Mr. Musing’s
extensive and distinguished career at Johnson & Johnson, he established
numerous strategic and global partnerships on many different fronts. The
knowledge gained from those accomplishments is sure to offer valuable insight
and direction to the company going forward.”
“Mr. Musing’s hands-on industry experience, in addition to having had direct
responsibility for establishing various new product collaborations, will prove
invaluable as we prepare to commence Phase III clinical trials on three of our
hormone therapy development candidates,” said Robert G. Finizio, Chief
“I am excited to join the TherapeuticsMD Board at this pivotal time in the
company’s development,” said Mr. Musing. “I look forward to working closely
with this experienced and dedicated senior management team.”
Mr. Musing presently serves on the Board of Directors of Delphi Digital, Inc.
and is Chairman of the Scientific Advisory Board of Noble Capital Financial
Markets. In addition, he has been a member of the Board of Directors of iBio,
Mr. Musing received his Master’s Degree in Biological Sciences from the
University of Brussels, and his Graduate Degree in Economics and Financial
Sciences from the University of Antwerp, in Belgium.
About TherapeuticsMD, Inc.
TherapeuticsMD, Inc. is a women’s healthcare company focused on developing and
commercializing products targeted exclusively for women. We manufacture and
distribute branded and generic prescription prenatal vitamins, as well as
over-the-counter vitamins and cosmetics, under our vitaMedMD^® and
BocaGreenMD™ brands. We are currently developing advanced hormone therapy
pharmaceutical products designed to alleviate the symptoms of and reduce the
health risks resulting from menopause-related hormone deficiencies. We are
also evaluating various other potential indications for our hormone
technology, including oral contraception, preterm birth, vulvar and vaginal
atrophy, and premature ovarian failure. More information is available at the
following websites: www.therapeuticsmd.com, www.vitamedmd.com,
www.vitamedmdrx.com, and www.bocagreenmd.com.
vitaMedMD^® is a registered trademark and TherapeuticsMD™ and BocaGreenMD™ are
trademarks of TherapeuticsMD, Inc.
Except for the historical information contained herein, the matters set forth
in this press release, including statements regarding the Company’s beliefs
that Mr. Musing is sure to offer valuable insight and direction to the company
going forward and that Mr. Musing’s experience will prove invaluable as the
company prepares to commence Phase III clinical trials on three of its hormone
therapy development candidates, are forward-looking statements within the
meaning of the “safe harbor” provisions of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements are subject to risks and
uncertainties that may cause actual results to differ materially, including
but not limited to: Mr. Musing’s ability to apply his experience to the
company; timely and successful completion of clinical studies and the results
thereof; the risks and uncertainties associated with economic and market
conditions; risks and uncertainties associated with TherapeuticsMD’s business
and finances in general; and other risks detailed in TherapeuticsMD’s filings
with the U.S. Securities and Exchange Commission including its annual report
on Form 10-K filed on March 12, 2013, reports on Form 10-Q and Form 8-K, and
other such filings. These forward-looking statements are based on current
information that may change. Investors are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date
of this press release. All forward-looking statements are qualified in their
entirety by this cautionary statement, and TherapeuticsMD undertakes no
obligation to revise or update any forward-looking statement to reflect events
or circumstances after the issuance of this press release.
Dan Cartwright, 561-961-1930
Chief Financial Officer
Lisa M. Wilson, 917-543-9932
Press spacebar to pause and continue. Press esc to stop.